# US 2025/0145625 A1 · Pyrazolopyrimidine derivative and anticancer pharmaceutical composition containing same as active ingredient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145625 A1
- Document ID: US20250145625A1
- Status: Published application
- Kind: A1
- Application number: 18/725,482
- Filed: 2022-12-30
- Published: 2025-05-08
- Earliest claimed: 2021-12-30
- Assignees: Korea Research Institute of Chemical Technology; UIF (University Industry Foundation), Yonsei University
- Applicants: Korea Research Institute of Chemical Technology; Uif (University Industry Foundation), Yonsei University
- Inventors: Joon JEONG; Hye Kyoung SHIN; Sun Joo AHN; Hee Jong LIM; Jin Sook SONG; Seong Hwan KIM; Chong Hak CHAE; Eun Hye KIM; Ji Hye CHOI; Jong Seung LIM; Eun Soo JANG; Jin Woo SONG; Do Hyun KIM
- Web page: https://patentgrep.com/patent/US20250145625A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a pharmaceutical composition for the prevention or treatment of tumors, containing a novel pyrazolopyrimidine compound or a pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition is administered in combination with other anticancer agents, and thus can be effectively used as a composition for preventing or treating cancer.

## Claims

### Claim 1

A compound of Chemical Formula 1 below, or a hydrate, solvate, prodrug, or pharmaceutically acceptable salt thereof:
where:
R1 is substituted or unsubstituted C6-C12 aryl, substituted or unsubstituted heteroaryl of 5 to 12 atoms, or substituted or unsubstituted heterocycloalkyl of 5 to 12 atoms;
the substituted aryl, heteroaryl, or heterocycloalkyl has one or more hydrogen atoms in a ring thereof, each of which is independently substituted with halogen, C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C1-C6 alkoxy C1-C6 alkoxy, C(═O), carbamoyl, C1-C6 alkylaminoketone, C1-C6 alkoxycarbonyl, C1-C6 alkylsulfonamino, C3-C6 cycloalkylcarboxamido or C3-C6 cycloalkylaminoketone;
R2 is substituted or unsubstituted —NH—(C6-C12)aryl, substituted or unsubstituted —NH—(C3-C6)cycloalkyl, substituted or unsubstituted —NH—(C3-C6)heterocycloalkyl, or —NH—(CH2)m—(C3-C6)heterocycloalkyl (where m is an integer of 0, 1, or 2);
the substituted aryl, cycloalkyl, or heterocycloalkyl has one or more hydrogen atoms in a ring thereof, each of which is independently substituted with halogen, C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxy, or halo C1-C6 alkoxy;
R3 is substituted or unsubstituted —NH—(C6-C12)aryl or substituted or unsubstituted —NH—(C3-C6)cycloalkyl;
the substituted aryl or cycloalkyl has one or more hydrogen atoms in a ring thereof, each of which is independently substituted with halogen, C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C1-C6 alkoxy C1-C6 alkoxy, substituted or unsubstituted morpholine, substituted or unsubstituted piperazine, substituted or unsubstituted triazole, C1-C6alkylaminoketone, substituted or unsubstituted —C(═O)-morpholine, substituted or unsubstituted —C(═O)-piperazine, or substituted or unsubstituted —C(═O)NH-piperidine; and
the substituted morpholine, piperazine, triazole, —C(═O)-morpholine, —C(═O)-piperazine, or —C(═O)NH-piperidine has one or more hydrogen atoms, each of which is independently substituted with halogen, C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxy.

### Claim 2 (depends on 1)

The compound of claim 1 having Chemical Formula 2-1 below, or a hydrate, solvate, prodrug, or pharmaceutically acceptable salt thereof:
where:
R1 is substituted or unsubstituted pyridine, substituted or unsubstituted pyrazole, substituted or unsubstituted imidazole, substituted or unsubstituted furan, substituted or unsubstituted thiazole, substituted or unsubstituted pyrimidine, substituted or unsubstituted triazole, substituted or unsubstituted oxadiazole, substituted or unsubstituted oxazole, substituted or unsubstituted isoxazole, substituted or unsubstituted benzimidazole, substituted or unsubstituted indazole, substituted or unsubstituted benzoxazole, substituted or unsubstituted 1,3,4-oxadiazolone, substituted or unsubstituted benzimidazole, substituted or unsubstituted indazole, or substituted or unsubstituted benzoxazole;
the substituted pyridine, pyrazole, imidazole, furan, thiazole, pyrimidine, triazole, oxadiazole, oxazole, isoxazole, benzimidazole, indazole, benzoxazole, 1,3,4-oxadiazolone, benzimidazole, indazole, or benzoxazole has one or more hydrogen atoms in a ring thereof, each of which is independently substituted with halogen, C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C1-C6 alkoxy C1-C6 alkoxy, C(═O), carbamoyl, C1-C6 alkylaminoketone, C1-C6 alkoxycarbonyl, C1-C6 alkylsulfonamino, C3-C6 cycloalkylcarboxamido or C3-C6 cycloalkylaminoketone;
R4 is substituted with hydrogen or C1-C6 alkyl;
E is substituted with —NHR4,
A is substituted with NH;
B is substituted with O, S, or CH2;
D is substituted with O or NR4;
m is an integer of 0, 1, or 2; and
n is an integer of 0 or 1.

### Claim 3 (depends on 1)

The compound of claim 1 having Chemical Formula 2-2 below, or a hydrate, solvate, prodrug, or pharmaceutically acceptable salt thereof:
where:
R1 is substituted or unsubstituted pyridine, substituted or unsubstituted pyrazole, substituted or unsubstituted imidazole, substituted or unsubstituted furan, substituted or unsubstituted thiazole, substituted or unsubstituted pyrimidine, substituted or unsubstituted triazole, substituted or unsubstituted oxadiazole, substituted or unsubstituted oxazole, substituted or unsubstituted isoxazole, substituted or unsubstituted benzimidazole, substituted or unsubstituted indazole, substituted or unsubstituted benzoxazole, substituted or unsubstituted 1,3,4-oxadiazolone, substituted or unsubstituted benzimidazole, substituted or unsubstituted indazole, or substituted or unsubstituted benzoxazole;
the substituted pyridine, pyrazole, imidazole, furan, thiazole, pyrimidine, triazole, oxadiazole, oxazole, isoxazole, benzimidazole, indazole, benzoxazole, 1,3,4-oxadiazolone, benzimidazole, indazole, or benzoxazole has one or more hydrogen atoms in a ring thereof, each of which is independently substituted with halogen, C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C1-C6 alkoxy C1-C6 alkoxy, C(═O), carbamoyl, C1-C6 alkylaminoketone, C1-C6 alkoxycarbonyl, C1-C6 alkylsulfonamino, C3-C6 cycloalkylcarboxamido or C3-C6 cycloalkylaminoketone;
R4 is substituted with hydrogen or C1-C6 alkyl;
D is substituted with O or NR4;
m is an integer of 0, 1, or 2; and
n is an integer of 0 or 1.

### Claim 4

A compound of Chemical Formula 3-1 below, or a hydrate, solvate, prodrug, or pharmaceutically acceptable salt thereof:
where:
R1 is substituted or unsubstituted pyridine, substituted or unsubstituted pyrazole, substituted or unsubstituted imidazole, substituted or unsubstituted furan, substituted or unsubstituted thiazole, substituted or unsubstituted pyrimidine, substituted or unsubstituted triazole, substituted or unsubstituted oxadiazole, substituted or unsubstituted oxazole, substituted or unsubstituted isoxazole, substituted or unsubstituted benzimidazole, substituted or unsubstituted indazole, substituted or unsubstituted benzoxazole, substituted or unsubstituted 1,3,4-oxadiazolone, substituted or unsubstituted benzimidazole, substituted or unsubstituted indazole, or substituted or unsubstituted benzoxazole;
the substituted pyridine, pyrazole, imidazole, furan, thiazole, pyrimidine, triazole, oxadiazole, oxazole, isoxazole, benzimidazole, indazole, benzoxazole, 1,3,4-oxadiazolone, benzimidazole, indazole, or benzoxazole has one or more hydrogen atoms in a ring thereof, each of which is independently substituted with halogen, C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C1-C6 alkoxy C1-C6 alkoxy, C(═O), carbamoyl, C1-C6 alkylaminoketone, C1-C6 alkoxycarbonyl, C1-C6 alkylsulfonamino, C3-C6 cycloalkylcarboxamido or C3-C6 cycloalkylamino;
R4 is substituted with hydrogen or C1-C6 alkyl;
A is substituted with NH;
B is substituted with O, S, or CH2;
D is substituted with O or NR4;
m is an integer of 0, 1, or 2; and
n is an integer of 0 or 1.

### Claim 5

A compound of Chemical Formula 3-2 below, or a hydrate, solvate, prodrug, or pharmaceutically acceptable salt thereof:
where:
R1 is substituted or unsubstituted pyridine, substituted or unsubstituted pyrazole, substituted or unsubstituted imidazole, substituted or unsubstituted furan, substituted or unsubstituted thiazole, substituted or unsubstituted pyrimidine, substituted or unsubstituted triazole, substituted or unsubstituted oxadiazole, substituted or unsubstituted oxazole, substituted or unsubstituted isoxazole, substituted or unsubstituted benzimidazole, substituted or unsubstituted indazole, substituted or unsubstituted benzoxazole, substituted or unsubstituted 1,3,4-oxadiazolone, substituted or unsubstituted benzimidazole, substituted or unsubstituted indazole, or substituted or unsubstituted benzoxazole;
the substituted pyridine, pyrazole, imidazole, furan, thiazole, pyrimidine, triazole, oxadiazole, oxazole, isoxazole, benzimidazole, indazole, benzoxazole, 1,3,4-oxadiazolone, benzimidazole, indazole, or benzoxazole has one or more hydrogen atoms in a ring thereof, each of which is independently substituted with halogen, C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C1-C6 alkoxy C1-C6 alkoxy, C(═O), carbamoyl, C1-C6 alkylaminoketone, C1-C6 alkoxycarbonyl, C1-C6 alkylsulfonamino, C3-C6 cycloalkylcarboxamido or C3-C6 cycloalkylaminoketone;
R4 is substituted with hydrogen or C1-C6 alkyl;
D is substituted with O or NR4;
m is an integer of 0, 1, or 2; and
n is an integer of 0 or 1.

### Claim 6 (depends on 1)

The compound of claim 1, or a hydrate, solvate, prodrug, or pharmaceutically acceptable salt thereof, wherein the compound represented by Chemical Formula 1 is selected from the group consisting of:
N4-cyclohexyl-3-(5-fluoropyridine-3-yl)-N6-(2-methoxy-4-morpholinophenyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 8-1);
3-(4-(cyclohexylamino)-6-((2-methoxy-4-morpholinophenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzamide (Compound 8-2);
methyl 4-(4-(cyclohexylamino)-6-((2-methoxy-4-morpholinophenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzoate (Compound 8-3);
N-(3-(4-(cyclohexylamino)-6-(2-methoxy-4-morpholinophenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl)cyclopropanecarboxamide (Compound 8-4);
3-(4-(cyclohexylamino)-6-((2-methoxy-4-morpholinophenyl)amino)-1H-pyrazolo [3,4-d]pyrimidin-3-yl)-N-methylbenzamide (Compound 8-5);
N-(3-(4-(cyclohexylamino)-6-((2-methoxy-4-morpholinophenyl)amino)-1H-pyrazolo [3,4-d]pyrimidin-3-yl)phenyl)methanesulfonamide (Compound 8-6);
N4-cyclohexyl-N6-(2-methoxy-4-morpholinophenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 8-7);
N4-cyclohexyl-N6-(2-methoxy-4-morpholinophenyl)-1-(4-methoxybenzyl)-3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 8-8);
N4-cyclohexyl-N6-(4-morpholinocyclohexyl)-3-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 8-9);
N4-cyclohexyl-N6-(2-methoxy-4-morpholinophenyl)-3-(1-methyl-1H-pyrazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 8-10);
N4-cyclohexyl-3-(1-isopropyl-1H-imidazol-4-yl)-N6-(2-methoxy-4-morpholinophenyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 8-11);
N4-cyclohexyl-3-(1-(difluoromethyl)-1H-pyrazol-4-yl)-N6-(2-methoxy-4-morpholinophenyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 8-12);
N4-cyclohexyl-N6-(2-methoxy-4-morpholinophenyl)-3-(1-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 8-13);
N4-cyclohexyl-3-(furan-2-yl)-N6-(2-methoxy-4-morpholinophenyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 8-14);
N4-cyclohexyl-N6-(2-methoxy-4-morpholinophenyl)-3-(thiazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 8-15);
3-(1H-benzo[d]imidazol-5-yl)-N4-cyclohexyl-N6-(2-methoxy-4-morpholinophenyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 8-16);
N4-cyclohexyl-3-(1H-indazol-5-yl)-N6-(2-methoxy-4-morpholinophenyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 8-17);
N4-cyclohexyl-N6-(2-methoxy-4-morpholinophenyl)-3-(2-methylbenzo[d]oxazol-6-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 8-18);
N4-cyclohexyl-N6-(2-methoxy-4-morpholinophenyl)-3-(1-methyl-1H-imidazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 8-19);
N4-cyclohexyl-3-(isoxazol-4-yl)-N6-(2-methoxy-4-morpholinophenyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine(Compound 8-20);
3-(Isoxazol-4-yl)-N6-(2-methoxy-4-morpholinophenyl)-N4-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine(Compound 8-21);
N6-(2-methoxy-4-morpholinophenyl)-3-(oxazol-2-yl)-N4-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine(Compound 8-22);
N6-(2-methoxy-4-morpholinophenyl)-3-(1-methyl-1H-pyrazol-4-yl)-N4-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 8-23);
3-(1-(difluoromethyl)-1H-pyrazol-4-yl)-N6-(2-methoxy-4-morpholinophenyl)-N4-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 8-24);
N6-(2-methoxy-4-morpholinophenyl)-3-(1-methyl-1H-pyrazol-3-yl)-N4-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 8-25);
N6-(2-methoxy-4-morpholinophenyl)-3-(1H-pyrazol-4-yl)-N4-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 8-26);
N6-(2-methoxy-4-morpholinophenyl)-3-(pyridin-3-yl)-N4-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 8-27);
N6-(2-methoxy-4-morpholinophenyl)-3-(pyridin-4-yl)-N4-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 8-28);
N6-(2-methoxy-4-morpholinophenyl)-3-(pyrimidin-5-yl)-N4-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 8-29);
N4-cyclohexyl-3-(1-methyl-1H-pyrazol-4-yl)-N6-(4-morpholinocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 8-30);
N4-cyclohexyl-N6-(2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 11-1);
N4-cyclohexyl-N6-(2-methoxy-4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 11-2);
4-((4-(cyclohexylamino)-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-3-methoxy-N-methylbenzamide (Compound 11-3);
(4-((4-(cyclohexylamino)-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-3-methoxyphenyl)(morpholino)methanone (Compound 11-4);
(4-((4-(cyclohexylamino)-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-3-methoxyphenyl)(4-methylpiperazin-1-yl)methanone (Compound 11-5);
4-((4-(cyclohexylamino)-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide (Compound 11-6);
N4-cyclohexyl-N6-(2-methoxy-4-morpholinophenyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 14-1);
N4-cyclohexyl-N6-(2-methoxy-4-morpholinophenyl)-3-(1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 14-2);
5-(4-(cyclohexylamino)-6-((2-methoxy-4-morpholinophenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 14-3);
N4-cyclohexyl-N6-(2-methoxy-4-morpholinophenyl)-3-(oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 18-1);
N4-cyclohexyl-3-(1H-imidazol-5-yl)-N6-(2-methoxy-4-morpholinophenyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 18-2);
N4-cyclohexyl-N6-(2-methoxy-4-morpholinophenyl)-3-(1H-1,2,3-triazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 21-1);
N4-cyclohexyl-N6-(2-methoxy-4-morpholinophenyl)-3-(1-methyl-1H-1,2,3-triazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 21-2);
N6-(2-methoxy-4-morpholinophenyl)-3-(1-methyl-1H-1,2,3-triazol-4-yl)-N4-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 21-3);
N4-cyclohexyl-N6-(2-isopropoxy-4-morpholinophenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Compound 26-1);
4-(cyclohexyloxy)-N-(2-methoxy-4-morpholynophenyl)-3-(1-methyl-1H-pyrazole-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-6-amine (Compound 26-2);
N6-(2-methoxy-4-morpholinophenyl)-3-(1-methyl-1H-pyrazol-4-yl)-N4-(1-methylpiperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine(Compound 28-1);
N6-(2-methoxy-4-morpholinophenyl)-3-(oxazol-5-yl)-N4-(tetra-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine(Compound 33-1);
3-methoxy-N-methyl-4-((3-(oxazol-5-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)benzamide(Compound 33-2);
N6-(2-methoxy-4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-3-(oxazol-5-yl)-N4-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine(Compound 33-3);
N6-(2-methoxy-4-morpholinophenyl)-3-(1-methyl-1H-pyrazol-4-yl)-N4-((tetrahydrofuran-2-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine(Compound 8-34); and
3-(isoxazol-4-yl)-N6-(2-methoxy-4-morpholinophenyl)-N4-((tetrahydrofuran-2-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine(Compound 8-35).

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A pharmaceutical composition for prevention or treatment of cancer, the pharmaceutical composition comprising a therapeutically effective amount of the compound of any one of claims 1 to 6, or a hydrate, solvate, prodrug, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein the pharmaceutical composition exhibits inhibitory activity on at least one protein kinase selected from the group consisting of TTK(h), ALK(h), IR(h) activated, IRR(h), and LTK(h).

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8, wherein the pharmaceutical composition exhibits inhibitory activity on TTK kinase.

### Claim 10 (depends on 7)

The pharmaceutical composition of claim 7, wherein the cancer is a solid cancer or blood cancer.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, wherein the solid cancer is any one of brain tumor, benign astrocytoma, malignant astrocytoma, pituitary adenoma, meningioma, primary central nervous system lymphoma, oligodendroglioma, craniopharyngioma, ependymoma, brain stem glioma, head and neck tumor, laryngeal cancer, oropharyngeal cancer, nasal cavity cancer, nasopharyngeal tumor, salivary gland tumor, hypopharyngeal cancer, thyroid cancer, oral cavity tumor, oral squamous cell carcinoma, Barrett's esophagus, thoracic tumor, small cell lung cancer, non-small cell lung cancer, thymic carcinoma, mediastinal neoplasm, esophageal cancer, neuroglioma, breast cancer, male breast cancer, triple negative breast cancer (TNBC), breast sporadic basaloid carcinoma (BLC), abdominal tumor, stomach cancer, liver cancer, gallbladder cancer, biliary tract cancer, pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC), small intestine cancer, colon cancer, anal cancer, colonic mucosal adenoma, bladder cancer, kidney cancer, male genital tract tumor, penile cancer, prostate cancer, female genital tract tumor, cervical cancer, endometrial cancer, ovarian cancer, ovarian adenocarcinoma, uterine sarcoma, vulvar intraepithelial neoplasia, vaginal cancer, female external genitalia cancer, female urethral cancer, and skin cancer.

### Claim 12 (depends on 10)

The pharmaceutical composition of claim 10, wherein the blood cancer is any one of leukemia, malignant lymphoma, multiple myeloma, and aplastic anemia.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6)

A pharmaceutical composition for the prevention or treatment of cancer, the pharmaceutical composition comprising co-administration of the compound of any one of claims 1 to 6 and an anticancer drug.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13, wherein the anticancer drug is selected from a taxane-based anticancer drug, an antitumor alkylating agent, an antitumor antimetabolite, an antitumor antibiotic, a plant-derived antitumor agent, an antitumor platinum complex, an antitumor camptothecin derivative, an antitumor kinase inhibitor, an antitumor antibody, a hormonal antitumor agent, an antitumor viral agent, and an angiogenesis inhibitor.

### Claim 15 (depends on 13)

The pharmaceutical composition of claim 13, wherein the taxane-based anticancer drug is selected from paclitaxel, docetaxel, or cabazitaxel.
